Coherus Oncology (CHRS) The Citizens JMP Life Sciences Conference 2025 summary

Strategic focus and pipeline overview

• Transitioning to an innovative oncology focus, highlighted by the rebranding to Coherus Oncology and prioritizing proprietary assets.

• Toripalimab (Loqtorzi) is positioned as a differentiated PD-1 inhibitor, approved for nasopharyngeal cancer and established as the standard of care per NCCN guidelines.

• Combination development strategy includes internal pipeline assets and external partnerships, aiming for broad clinical adoption and future market expansion as competitors' patents expire.

• CCR8 (CHS-114) and casdozokitug are key pipeline assets, with first-in-class U.S. patient data and promising early efficacy in targeted tumor types.

• Focused development in tumor types with strong preclinical and clinical signals, particularly liver and lung for casdozokitug, and head and neck for CCR8.

Clinical data and differentiation

• Toripalimab demonstrates activity in low PD-1 state tumors and is being developed in multiple combinations, including pivotal trials with partners.

• CCR8 program shows high selectivity, minimal toxicity up to 1,200 mg, and early proof of principle with partial responses in head and neck cancer.

• Casdozokitug achieved a 17%-18% complete response rate in first-line liver cancer, an unprecedented result in this setting.

• Both programs are advancing to larger studies, with key efficacy and safety data expected early next year.

• Objective response rate targets are 20% ORR and nine-month PFS for head and neck, and maintaining CR rates above 15% for liver cancer.

Commercial execution and financial position

• Loqtorzi launch is progressing as planned, with strong uptake due to compelling data and NCCN guideline positioning.

• Market potential for Loqtorzi is estimated at $150-$200 million annually within three years, targeting 2,000 patients and 4,000 physicians.

• Divestiture of biosimilar assets, including UDENYCA, generated $800 million, enabling repayment of $500 million in debt and a $250 million cash balance.

• Current cash runway supports ongoing development and commercial activities for several years.

• Execution track record spans regulatory, development, and commercial success, positioning the company for future growth in oncology.